DOI: https://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20222649
Published: 2022-10-26

Evaluating the demographic profile and mapping the prevalence of overactive bladder in benign prostrate hypertrophy patients: a retrospective, observational study

Sandesh Warudkar, Amit B. Jain, Nilanj Dave, Ankita Shah

Abstract


Background: The objectives of the study was to evaluate the demographic profile of benign prostatic hyperplasia (BPH) patients and prevalence of overactive bladder (OAB) among these patients.

Methods: A real-world, retrospective, observational study (DEMO-2) on BPH patients was conducted across India from April-2021 to March-2022. Demographics, BPH characteristics, status of OAB, and their management were evaluated.

Results: A total of 5881 BPH patients were included with a mean age of 65.3 years and mean BPH duration of 3.2 years. Majority (80.98%) of the patients had associated comorbidity; hypertension (50.2%), diabetes (26.9%) and dyslipidemia (13%) were the most common. Majority (63%) of the patients complained of incomplete bladder emptying. In BPH patients, 29.9% had OAB. These patients had a higher mean prostate volume (44.96 vs. 42.17 cc) and prostate specific antigen (PSA) levels (4.11 vs. 3.79 ng/ml) versus BPH patients without OAB. For BPH, tamsulosin was the most prescribed drug (85.90%) followed by dutasteride (66.90%); tamsulosin + dutasteride was most common combination therapy (32.6%).  In BPH patients with OAB, 82% received OAB medications and solifenacin (63.9%) was the most common medication.

Conclusions: Majority of the BPH patients were between the ages of 50-75 years. Tamsulosin was the most commonly prescribed medication in BPH patients. Combination of tamsulosin and dutasteride was the mainstay of treatment. OAB was seen in 29.9% of the BPH patients, and solifenacin was the most commonly utilized (63.1%) medication in BPH patients with OAB. About 18% of these patients did not receive any specific medication for OAB. Adequate treatment strategies need to be adopted for BPH patients with OAB.


Keywords


Benign prostrate hypertrophy, BPH, Overactive bladder, OAB, Treatment

Full Text:

PDF

References


Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(9):S3-s14.

Thomas D, Chughtai B, Kini M, Te A. Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opinion on Emerging Drugs. 2017;22:201-12.

Rosen RC. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opinion Urol. 2006;16:11-9.

Soler R, Averbeck MA, Koyama MAH, Gomes CM. Impact of LUTS on treatment-related behaviors and quality of life: A population-based study in Brazil. Neurourol Urodyn. 2019;38:1579-87.

Abrams P. Nocturia: the major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol Supplements. 2005;3:8-16.

Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive Bladder Syndrome: Evaluation and Management. Curr Urol. 2018;11:117-25.

Stewart WF, Van Rooyen JB, Cundiff GW. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327-36.

McVary KT, Roehrborn CG, Avins AL. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793-803.

Raina SK, Razdan S, Nanda R. Prevalence of neurological disorders in children less than 10 years of age in RS Pura town of Jammu and Kashmir. J Pediatr Neurosci. 2011;6:103.

Roehrborn C, Walsh PC, Reitik AB, Vaughan ED. Etioloy, pathothysiology, epidemiology and natural history of binign prostatichyperplasia. Campbell′ s Urolo. Philadelphia: WB Saunders Company. 2002.

De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560-70.

Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol. 2001;54:935-44.

Joseph MA, Harlow SD, Wei JT. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906-14.

Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014;30:170-6.

Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2013;189:S102-6.

Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395-401.

Parsons JK, Messer K, White M. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur Urol. 2011;60:1173-80.

Muller RL, Gerber L, Moreira DM. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol. 2013;63:1115-21.

Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology 2006;68:1198-205.

Parsons JK, Bergstrom J, Barrett‐Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community‐dwelling men. BJU Int. 2008;101:313-8.

Sarma AV, Sauver JLS, Hollingsworth JM. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology. 2012;79:102-8.

Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol. 2009;182:1463-8.

Parsons J. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opinion Urol. 2011;21:1-4.

Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged≥ 80 years. Urology. 2008;72:318-321.

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474-9.

Loeb S, Kettermann A, Carter HB. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. J Urol. 2009;182:1458-62.

Bosch J, Tilling K, Bohnen A, Bangma C, Donovan J. Establishing normal reference ranges for prostate volume change with age in the population‐based Krimpen‐study: Prediction of future prostate volume in individual men. Prostate. 2007;67:1816-24.

Bosch JR, Bangma CH, Groeneveld FP, Bohnen AM. The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study. Eur Urol. 2008;53:819-27.

Roehrborn CG, McConnell JD, Lieber M. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999;53:473-80.

Yi Q-T, Gong M, Chen C-H, Hu W, Zhu R-J. Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life. BMC Urol. 2019;19:82.

Burnett AL, Walker DR, Feng Q. Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study. Neurourol Urodyn. 2020;39:1378-86.

Chapple CR. A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. Rev Urol. 2005;7(4):S22-30.

Tewari A, Narayan P. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy. Urology. 1999;53:14-20.

Amory JK, Wang C, Swerdloff RS. The effect of 5α-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metabol. 2007;92:1659-65.

McConnell JD, Roehrborn CG, Bautista OM. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med. 2003;349:2387-98.

Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-41.

Roehrborn CG, Malice M-P, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology. 2001;58:210-6.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:Cd005429.

McVary KT, Roehrborn C, Avins A. AUA guidelines: Management of BPH. Bethesda: American Urological Association, Education and Research, Inc. 2010.